CoLucid Pharmaceuticals Inc. (CLCD) announced Tuesday morning that its Phase 3 pivotal study of lasmiditan, for the treatment of migraine in adults, achieved both the primary and key secondary efficacy endpoints with statistical significance.
from RTT - Before the Bell http://ift.tt/2cAVGpx
via IFTTT
No comments:
Post a Comment